Sequence analysis of tau 3’untranslated region and saitothin gene in sporadic progressive supranuclear palsy

M Ezquerra, J Campdelacreu, E Muñoz, R Oliva, E Tolosa

J Neurol Neurosurg Psychiatry 2004;75:155–157

**Background:** The extended tau H1 haplotype has previously been described in association with progressive supranuclear palsy (PSP). Recently, a new gene called saitothin (STH), nested within an intron of tau, has been discovered. The Q7R polymorphism of STH appears to be related to late onset Alzheimer’s disease.

**Objectives:** To search for genetic changes in the 3’untranslated region (3’UTR) of tau and adjacent sequence LOC147077, and in the coding region of STH in PSP patients.

**Methods:** The study included 57 PSP patients and 83 healthy controls. The genetic analysis of each region was performed through sequencing. The Q7R polymorphism was studied through restriction enzyme and electrophoresis analysis.

**Results:** No mutations were found in the regions analysed. The QQ genotype of the STH polymorphism was over-represented in participants with PSP (91.5%) compared with control subjects (47%) (p<0.00001). This genotype co-segregated with the H1/H1 haplotype in our PSP cases.

**Conclusions:** Our results do not support a major role for the tau 3’UTR in PSP genetics. The QQ genotype of STH confers susceptibility for PSP and is in linkage disequilibrium with the H1/H1 haplotype.

Progressive supranuclear palsy (PSP) is a parkinsonian syndrome accompanied by supranuclear gaze palsy, pseudobulbar signs, axial dystonia, postural instability, frontal dementia, and a poor response to levodopa. In typical cases of PSP, aberrant forms of the microtubule associated protein tau precipitate in subcortical neurons and glial cells, leading to neurofibrillary tangles (NFTs). The NFTs and other abnormal filaments, found in many neurodegenerative diseases such as frontotemporal dementia (FTD), Alzheimer’s disease, or corticobasal ganglionic degeneration, are produced by hyperphosphorylated tau species. The tau gene is organised into 16 exons expanding among 100 kilobases of DNA on chromosome 17q21. In CNS neurons, exons 2, 3, and 10 are alternatively spliced allowing the expression of six different tau isoforms. In particular, the isoform carrying the alternatively spliced exon 10 has been found to be increased in PSP and FTD. Mutations in the 5’splice site and missense mutations in exons 9, 10, 12, and 13 have been described in many cases of familial frontotemporal dementia. Additionally, the allele A0 of a dinucleotide repeat polymorphism in the tau intron located between exons 9 and 10 has been found to be statistically associated with PSP. This association extends to other polymorphisms in tau which are in linkage disequilibrium leading to a 100 kilobases haplotype called H1, and an extended H1E haplotype that includes some neighbour genes covering 360 kilobases.

So far only four mutations in tau have been described in cases of atypical PSP: the R406W missense mutation, the S305S silent mutation, the homozygous delN296 mutation, and the missense R5L mutation. Many studies have failed to identify a causative mutation after analysing the entire coding and promoter regions of tau in typical PSP patients. Thus, these data suggest that a separate gene or other non-coding regions of tau could be responsible for PSP.

Recently, a gene called saitothin (STH) was discovered in the intron between exons 9 and 10 of tau. STH expression is similar to tau, and a polymorphism in this gene appears to be associated with late onset Alzheimer’s disease. In this work, we have analysed the tau 3’untranslated region (3’UTR), the adjacent locus LOC147077 (NEDO human cDNA sequencing project, unpublished), and STH in order to search for mutations or new polymorphisms in typical PSP patients.

**METHODS**

**Subjects**

From the neurology service of our hospital we recruited 57 unrelated subjects (26 male, 31 female), who met the clinical diagnostic criteria for probable PSP; 83 healthy controls (34 male, 49 female) were recruited from among patients’ spouses, and healthy volunteers. Informed consent was previously obtained from all participants. The mean age of patients at the onset of PSP was 70 (5.5) years, and the mean age of the controls was 68.9 (7.5) years.

**Genetic analysis**

Genomic DNA was extracted from peripheral blood using standard procedures. STH amplification, sequencing assay, and Q7R polymorphism detection were performed as previously described. The tau promoter polymorphism was also genotyped as previously described.

Three pairs of primers were designed in order to amplify different overlapping fragments of the whole tau 3’UTR using the DNAstar software. The sequences of the designed forward and reverse tau primers were: 5'-ATCTCAGAATGTCTCTCCAC-3' and 5'-GGCTTCCTCTCCCCACTCC-3' for fragment 1 (annealing 57°C); 5'-CAGTGGCAGTTGGAAGCAGGAAAG-3' and 5'-CCAGGCTCCTCAAGACATCAAG-3' for fragment 2 (annealing 62°C); and 5'-TGATGATGACCTCCTTAGAAA-3' and 5'-GTACCTCCTGCAACCAACC-3' for fragment 3 (annealing 57°C). For the amplification of the LOC147077 sequence the primers were 5'-GGTTTTCTCCTGTTG-3' and 5'-AGTCTCTAATCTCGTGTCCA-3' (annealing 56°C).

The PCR mix was constituted in a total volume of 25 µl and consisted of: 1 µl of each primer (30 pmol/µl); 4 µl of...
1.25 mM dNTPs; 0.1 units of Taq Expand polymerase (Boehringer, Mannheim, Germany); 2.5 μl of 10× Taq buffer; 1.5 mM of Cl₄Mg; 1 μl of DNA at 100 ng/μl; and 15.4 μl of distilled water. The purified sample was sequenced by cycle sequencing, using the Dye Terminator Cycle sequencing Ready Reaction (Perkin Elmer, Foster City, USA), and run on an ABI-prism automatic DNA sequencer (Perkin Elmer).

**Statistical analysis**

The genotypic and allelic distribution of the STH polymorphism was analysed with a χ² test. All analyses were performed using computer software SPSS 10.0 for Windows (SPSS, Chicago, USA).

**RESULTS**

Sequencing of the tau 3'UTR, the adjacent locus LOC147077, and the STH coding region showed no mutations in three subjects with sporadic PSP. Analysis of the STH Q7R polymorphism allowed us to identify three different genotypes in patients and controls (fig 1). The frequencies revealed that the QQ genotype was present in 91.2% of patients and in only 47% of controls (p < 0.000001).

The analysis of the tau promoter G(−221)C polymorphism in participants with PSP showed that the CC genotype cosegregated completely with the QQ genotype.

**DISCUSSION**

Many polymorphisms, in or near tau, have been described as associated with PSP and leading to an extended H1 haplotype. This association might be due to linkage disequilibrium between these polymorphisms and a hypothetical adjacent functional mutation responsible for the disease. The half-lives and subcellular localisation of specific mRNAs may depend on specific sequences in 3'UTR. Therefore, alterations in this region could potentially be responsible for some pathological processes. However, we did not find any genetic changes after sequencing this region and adjacent locus LOC147077 in three typical cases of PSP.

We found that the QQ genotype of the STH polymorphism was over-represented in our patients with PSP. This genotype was segregated with the H1 haplotype because it is in complete disequilibrium with the CC genotype of tau promoter G(−221)C polymorphism, which in turn segregates with this haplotype as we previously described. After sequencing the entire coding region of STH, we could not demonstrate additional mutations. Therefore, the STH polymorphism, which gives rise to an amino acid change, could behave as a risk factor for PSP. The exact function of STH is still unknown; however, the fact that STH and tau have very similar expression patterns suggests that these two proteins could function together in physiological or pathological processes. Interestingly, the QQ genotype is the opposite of the genotype associated with Alzheimer’s disease (RR). As STH nests in the intron between exons 9 and 10 of tau, we cannot rule out the possibility that STH polymorphism, through the regulation of exon 10 alternative splicing, may explain the different expression of tau isoforms in PSP and Alzheimer’s disease.

In conclusion, our results do not support a major pathogenic role of the tau 3'UTR in PSP genetics. The QQ genotype of the STH polymorphism may be considered a risk factor for PSP. Functional studies of STH could be very important in disclosing whether it plays a role in tau splicing or tau phosphorylation.

**ACKNOWLEDGEMENTS**

We acknowledge technical support provided by Ms Eva Caballero.

**Authors’ affiliations**

M Ezquerra, J Campdelacreu, E Muñoz, E Tolosa, Institut Clínic de Malalties del Sistema Nervios (ICMSN), Hospital Clínic Universitari, Barcelona, Spain

R Oliva, Genetics Service, Hospital Clínic Universitari, Barcelona, Spain

This study was supported by grants from the Society for PSP to E Tolosa and from the Hospital Clinic to J Campdelacreu.

Competing interest: none declared

Correspondence to: Dr Mario Ezquerra, Laboratorio de Neurologia Experimental (IDBAPS), Hospital Clinic Universitari, Villarreal, 170, 08036 Barcelona, Spain; ezquerra@clinic.ub.es

Received 25 December 2002

In revised form 20 May 2003

Accepted 23 July 2003

**REFERENCES**

1 Daniel SE, de Bruin VMS, Lees AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain 1995;118:59–70.


![Figure 1](image-url) Genotypes of the saitohin Q7R polymorphism. The different patterns were visualised after digestion of the PCR products with HinfI followed by electrophoresis in a 7% acrylamide gel and silver staining.

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Genotypes</th>
<th>QR (%)</th>
<th>RR (%)</th>
<th>Alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSP (n = 57)</td>
<td>QQ (%)</td>
<td>52 (91.2)</td>
<td>5 (8.8)</td>
<td>Q (%)</td>
</tr>
<tr>
<td>Controls (n = 83)</td>
<td>QQ (%)</td>
<td>39 (47)</td>
<td>40 (48.2)</td>
<td>R (%)</td>
</tr>
</tbody>
</table>

n, number. *p < 0.00001 (χ² test).
Sequence analysis of tau 3′untranslated region and saitojin gene in sporadic progressive supranuclear palsy

M Ezquerra, J Campdelacreu, E Muñoz, R Oliva and E Tolosa

J Neurol Neurosurg Psychiatry 2004 75: 155-157

Updated information and services can be found at:
http://jnnp.bmj.com/content/75/1/155

These include:

References
This article cites 21 articles, 6 of which you can access for free at:
http://jnnp.bmj.com/content/75/1/155#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: CNS (not psychiatric) (1945)
Cranial nerves (529)
Movement disorders (other than Parkinsons) (766)
Ophthalmology (842)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/